4-acetyl phenethylamine hydrochloride | 23279-67-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-acetyl phenethylamine hydrochloride
• 英文别名: 1-[4-(2-amino-ethyl)-phenyl]-ethanone hydrochloride；4-(2-aminoethyl)-acetophenone hydrochloride；1-[4-(2-Aminoethyl)phenyl]ethan-1-one hydrochloride；1-[4-(2-aminoethyl)phenyl]ethanone;hydrochloride
• CAS: 23279-67-6
• 化学式: C₁₀H₁₃NO*ClH
• mdl: MFCD16619118
• 分子量: 199.68
• InChiKey: YMKKEUKWLSTFCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.95
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-acetyl phenethylamine hydrochloride 、 2-((1R,3R)-1-acetoxy-3-((2S,3S)-N,3-dimethyl-2-((R)-1-methylpiperidine-2-carboxamido)pentanamido)-4-methylpentyl)thiazole-4-carboxylic acid 在 五氟苯酚 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以84%的产率得到C₃₆H₅₃N₅O₆S
  参考文献：
  名称：

  合成微管溶素类似物-树枝状聚合物偶联物在 C26 荷瘤小鼠中的化疗评价

  摘要：

  共轭改善！描述了在 C26 荷瘤小鼠中使用合成微管溶素类似物的聚合物药物递送。与给予磷酸盐缓冲盐水对照或游离微管溶素类似物的组相比，单剂量的这种偶联物（如图所示）导致小鼠的平均寿命增加 90%。此外，在研究结束时，给予聚合物制剂的小鼠中有 37% 没有肿瘤。

  DOI：

  10.1002/cmdc.201000377

文献信息

• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及具有通式I的羧酰胺化合物 1 其中，A、B、W、X、Y、Z、R 1 、R 2 、R 3 和k的含义如权利要求1中所述。此外，本发明还涉及制备上述羧酰胺的方法以及含有至少一种根据本发明的羧酰胺的药物组合物。由于它们对MCH受体的拮抗活性，根据本发明的药物组合物适合用于治疗代谢紊乱和/或饮食紊乱，特别是肥胖症、厌食症、暴食症、糖尿病。
• Hypoglycaemically and hypolipidaemically active derivatives of
  申请人：Boehringer-Mannheim GmbH

  公开号：US04207341A1

  公开（公告）日：1980-06-10

  Phenylacetic acid derivatives of the formula ##STR1## wherein A is an aryl radical optionally substituted by halogen, trifluoromethyl, alkyl, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino or aryloxy, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy, Y is a valency bond or an optionally branched alkylene radical containing up to 3 carbon atoms, and R.sub.1 and R.sub.2 each independently is hydrogen or a lower alkyl radical, or a physiologically compatible salt or ester thereof, exhibit marked hypoglycaemic and hypolipidaemic activity.

  Phenylacetic acid derivatives of the formula ##STR1## wherein A is an aryl radical optionally substituted by halogen, trifluoromethyl, alkyl, alkoxy, alkenyloxy, alkoxyalkoxy, alkyl-substituted amino or aryloxy, or a heterocyclic ring system optionally substituted by halogen, alkyl or alkoxy, Y is a valency bond or an optionally branched alkylene radical containing up to 3 carbon atoms, and R.sub.1 and R.sub.2 each independently is hydrogen or a lower alkyl radical, or a physiologically compatible salt or ester thereof, exhibit marked hypoglycaemic and hypolipidaemic activity.
• Heterocyclic compounds
  申请人：Zeneca Limited

  公开号：US05563141A1

  公开（公告）日：1996-10-08

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  一种通式为(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基基团；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基团；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其医药上可接受的盐和前药，用于治疗与 GPIIb-IIIa 结合的粘附分子介导的血小板聚集相关的疾病。还公开了新型化合物。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  一般式为(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基基团；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基团；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过黏附分子与GPIIb-IIIa结合介导的血小板聚集所涉及的疾病。还揭示了新型化合物。
• WITTE, E. -C.;WOLFF, H. P.;STEGMEIER, K.;PILL, J.
  作者：WITTE, E. -C.、WOLFF, H. P.、STEGMEIER, K.、PILL, J.

  DOI：——

  日期：——